Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine (Q43029925)

12 November 2017

title

Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine (English)

1 reference

12 November 2017

1 reference

1 reference

Houghton M

1 reference

12 November 2017

Polakos NK

1 reference

12 November 2017

Drane D

1 reference

12 November 2017

Cox J

1 reference

12 November 2017

Ng P

1 reference

12 November 2017

Selby MJ

1 reference

12 November 2017

Chien D

1 reference

12 November 2017

O'Hagan DT

1 reference

12 November 2017

Paliard X

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

12 November 2017

published in

Journal of Immunology

1 reference

12 November 2017

volume

166

1 reference

12 November 2017

1 reference

12 November 2017

page(s)

3589-3598

1 reference

Binding of hepatitis C virus to CD81

12 November 2017

cites work

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1126/SCIENCE.282.5390.938

Analysis of successful immune responses in persons infected with hepatitis C virus

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Antigen recognition by class I-restricted T lymphocytes

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Size of IgG-opsonized particles determines macrophage response during internalization

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Kinetics, localization and cytokine profile of T cell responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMS

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Vaccination of chimpanzees against infection by the hepatitis C virus

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Priming in vivo and quantification in vitro of class I MHC-restricted cytotoxic T cells to human papilloma virus type 11 early proteins (E6 and E7) using immunostimulating complexes (ISCOMs).

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Quantification of the number of cytotoxic T cells specific for an immunodominant HCV-specific CTL epitope primed by DNA immunization

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Genetic organization and diversity of the hepatitis C virus

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Capture and processing of exogenous antigens for presentation on MHC molecules.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Heterologous protection against influenza by injection of DNA encoding a viral protein

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepat

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

The scientific challenge of hepatitis C.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

T-lymphocyte response to hepatitis C virus in different clinical courses of infection

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Analysis of a successful immune response against hepatitis C virus

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Pinocytosis and phagocytosis: the effect of size of a particulate substrate on its mode of capture by rat peritoneal macrophages cultured in vitro

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Mechanisms of MHC class I--restricted antigen processing

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Sequence analysis of the core gene of 14 hepatitis C virus genotypes

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Adjuvants--a classification and review of their modes of action

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Diagnosis of hepatitis C virus (HCV) infection using an immunodominant chimeric polyprotein to capture circulating antibodies: reevaluation of the role of HCV in liver disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Mamu-I: a novel primate MHC class I B-related locus with unusually low variability

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

T-cell–mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Genetic Heterogeneity of Hepatitis C Virus: Quasispecies and Genotypes

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms) and oil-in-water vaccines.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.4049/JIMMUNOL.166.5.3589

Identifiers

DOI

10.4049/JIMMUNOL.166.5.3589

1 reference

12 November 2017

1 reference